Insomnia Market Set to Soar, Projected to Reach $6.3 Billion by 2030 with a Steady CAGR of 3.9%

The bustling market of sleeplessness, known as insomnia, witnessed a remarkable valuation of $4.3 billion in the year 2020. With its relentless growth trajectory, it is poised to ascend even further, reaching an astonishing $6.3 billion by the year 2030. This rapid advancement is anticipated to manifest at an impressive compound annual growth rate (CAGR) of 3.9% from 2021 to 2030, solidifying insomnia’s position as a lucrative and thriving industry.

The staggering expansion of the global insomnia market is primarily propelled by a myriad of factors. One of the key drivers is the escalating prevalence of various sleep disorders, including insomnia and parasomnias. Additionally, the rise in mental depression and other painful conditions has contributed significantly to this market growth. Mental depression often leads to sleep difficulties, as reported by the World Health Organization (WHO), which estimates that approximately 280 million people worldwide suffer from depression. Consequently, the increase in mental depression across the global population directly contributes to the growth of the insomnia market.

Request Sample PDF Brochure: https://www.alliedmarketresearch.com/request-sample/2373

Key Market Players

zydus cadila, VIATRIS INC, EISAI, CO. LTD, merck kgaa, darmstadt, germany, Sanofi, Pfizer Inc., Vanda Pharmaceuticals Inc., Takeda Pharmaceutical Company Ltd, CURRAX PHARMACEUTICALS LLC, MINERVA NEUROSCIENCES INC

The insomnia market can be classified based on therapy type and region.

By Therapy Type:

1. Non-Pharmacological Therapy: This includes treatment approaches that do not involve the use of medication. Non-pharmacological therapies for insomnia often focus on behavior modifications, relaxation techniques, cognitive behavioral therapy (CBT), sleep hygiene practices, and alternative therapies such as acupuncture or herbal remedies.
2. Pharmacological Therapy: This category encompasses treatments that involve the use of medications to alleviate insomnia symptoms. Pharmacological therapies for insomnia include prescription drugs such as sedatives, hypnotics, benzodiazepines, non-benzodiazepine receptor agonists, and melatonin receptor agonists.

By Region:

1. North America: This region comprises the United States, Canada, and Mexico. North America has a significant presence in the insomnia market, driven by a high prevalence of sleep disorders and a robust healthcare infrastructure. The region is also characterized by advanced research and development activities in the field of sleep medicine.
2. Europe: This region includes countries such as Germany, France, the United Kingdom, Italy, Spain, and the rest of Europe. Europe has a considerable market share in the insomnia industry due to the increasing awareness about sleep disorders and the availability of advanced treatment options. The region is also known for its strong emphasis on research and innovation in sleep medicine.
3. Asia-Pacific: This region comprises Japan, China, Australia, India, South Korea, Taiwan, and the rest of Asia-Pacific. Asia-Pacific is a rapidly growing market for insomnia treatment due to factors such as a large population, increasing healthcare expenditure, and rising awareness about sleep disorders. The region is witnessing significant advancements in healthcare infrastructure and the adoption of sleep therapies.
4. LAMEA: LAMEA stands for Latin America, Middle East, and Africa. It includes countries such as Brazil, Turkey, Saudi Arabia, the Republic of South Africa, and the rest of LAMEA. This region is experiencing a gradual increase in the prevalence of sleep disorders, leading to a growing demand for insomnia treatments. The expanding healthcare infrastructure and rising awareness about sleep disorders contribute to the market growth in this region.

Speak To Analyst: https://www.alliedmarketresearch.com/connect-to-analyst/2373